- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05307744
Efeitos do Lactobacillus Plantarum PS128 em crianças com TEA
Efeitos do Lactobacillus Plantarum PS128 em crianças com transtorno do espectro do autismo
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Taoyuan, Taiwan
- Chang Gung Memorial Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- (1) Age 7 to 12 years old.
- (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
- (3) Normal control group: Children without autism spectrum disorder.
Exclusion Criteria:
- (1) Receiving antibiotics within one month.
- (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
- (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
- (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
- (5) Those with a history of cancer.
- (6) Those who are allergic to lactic acid bacteria.
- (7) Not eligible judged by PI
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: PS128
Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks. |
Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg. |
|
Comparador de Placebo: Placebo
Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks. |
The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose. |
|
Sem intervenção: Normal control
Normal control group are enrolled by invitation from the age and gender matched healthy children. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes of Total Scores of Social Responsiveness Scale
Prazo: Baseline, Week 12 and Week 16
|
Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness. |
Baseline, Week 12 and Week 16
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes of Total Scores of Repetitive Behavior Scale-Revised
Prazo: Baseline, Week 12 and Week 16
|
Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Child Behavior Checklist
Prazo: Baseline, Week 12 and Week 16
|
Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The score ranges from 0-240. The lower scores stand for better behavioral and emotional regulation. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Adaptive Behavior Assessment System
Prazo: Baseline, week 12 and Week 16
|
Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior. |
Baseline, week 12 and Week 16
|
|
Changes in Accuracy of Frith-Happe Animation
Prazo: Baseline, Week 12 and Week 16
|
A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition. |
Baseline, Week 12 and Week 16
|
|
Changes in Accuracy of Eyes Task
Prazo: Baseline, Week 12 and Week 16
|
An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Aberrant Behavior Checklist
Prazo: Baseline, Week 12 and Week 16
|
Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The score ranges from 0-174. The lower scores stand for less aberrant behavior. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Emotional Dysregulation Inventory
Prazo: Baseline, Week 12 and Week 16
|
Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Parenting Stress Index, Fourth Editon
Prazo: Baseline, Week 12 and Week 16
|
Parenting Stress Index is a parents' report questionnaire for parenting stress. The score ranges from 0-180. The lower scores stand for lower parenting stress. |
Baseline, Week 12 and Week 16
|
|
Assessment of Clinical Global Impression-Severity of Illness
Prazo: Week 12 and Week 16
|
The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The score ranges from 1-7. CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse. |
Week 12 and Week 16
|
|
Assessment of Patient Global Impression of Change
Prazo: Week 12 and Week 16
|
The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. The score ranges from 1-7. Patients rate their change as "1=very much improved ," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse)." |
Week 12 and Week 16
|
|
Gut Microbiota-Relative Abundance of Bifidobacterium Faecale
Prazo: Baseline and Week 12
|
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota |
Baseline and Week 12
|
|
MRI T1
Prazo: Baseline and Week 12
|
Brain structural volumes (cm²). The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal
Prazo: Baseline and Week 12
|
Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Diffusion Tensor Imaging (DTI) - FA
Prazo: Baseline and Week 12
|
Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Safety Assessment - Albumin
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as albumin (3.5-5.4 g/dl). |
Baseline and Week 12
|
|
Safety Assessment - Total Protein
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as total protein (6.4-8.3 g/dl). |
Baseline and Week 12
|
|
Safety Assessment - ALP
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as ALP (135-320 U/L). |
Baseline and Week 12
|
|
Safety Assessment - Total Bilirubin
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as total bilirubin (0.3-1.2 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - T-Cholesterol
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL). |
Baseline and Week 12
|
|
Safety Assessment - Uric Acid
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as uric acid (<7.0 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - BUN
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as BUN (7-25 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - Creatinine
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as creatinine (0.2-1.0 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - AST
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as AST (13-40 U/L). |
Baseline and Week 12
|
|
Safety Assessment - ALT
Prazo: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as ALT (7-40 U/L). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - MPO
Prazo: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-1β
Prazo: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - TGF-β1
Prazo: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - Eotaxin
Prazo: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-6
Prazo: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Serotonin
Prazo: Baseline and Week 12
|
Oxidative stress is assessed via Serotonin (ng/mL). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - GABA
Prazo: Baseline and Week 12
|
Oxidative stress is assessed via GABA (μmol/L). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Cortisol
Prazo: Baseline and Week 12
|
Oxidative stress is assessed via Cortisol (6-10am 4.82-19.5, 4-8pm 2.47-11.9, μg/dl). |
Baseline and Week 12
|
|
Gut Microbiota-Relative Abundance of Lactiplantibacillus Plantarum
Prazo: Baseline and Week 12
|
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota. |
Baseline and Week 12
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 202101416A3
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .